NCT03899155: Pan Tumor Rollover Study
- State
- Under way
- Phase
- Phase 2
- People
- 1,500 planned
- Started
- 9 Aug 2019
- Primary completion
- 25 Aug 2029
- Arms
- E11: Pembrolizumab Monotherapy
- Results
- None posted
- 2 Apr 2019: Trial registered
- 9 Aug 2019: Trial started
A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set
Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.
Also followed for narrower conditions: Carcinosarcoma, Endometrial Neoplasms, Fallopian Tube Neoplasms, Leukoplakia, Neoplasm Metastasis, Squamous Cell Carcinoma of Head and Neck
Also known as Keytruda, Keytruda qlex component pembrolizumab, Pembrolizumab 200 mg, Pembrolizumab Injection [Keytruda], Pembrolizumab SC.
Registries searched: ClinicalTrials.gov, through 17 Nov 2026.